Can Modicare Reshape India’s Health Care Paradigm?
India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?
You may also be interested in...
Roche Pharma India CEO and managing director, V Simpson Emmanuel, outlines the company's multi-forked approach, including collaborating with a crowdfunding platform, to move the access and treatment needle for Evrysdi in India. The Swiss firm, along with industry associations, also suggests the need for a formal accelerated regulatory pathway in India for rare diseases.
India’s government has hiked healthcare spending in its new budget by 13.5% ahead of national elections, earmarking the lion’s share for its flagship new health insurance scheme for the nation’s poorest half-billion people. But outlays for the stretched core public health-delivery system have stagnated.
Novartis India’s managing director has quit - the second time in 2018 that the Swiss multinational finds the corner office vacated.